Spohn G - Search Results

1

Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes.

Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, Schwarz K, Johansen P, Jennings GT, Bachmann MF. Spohn G, et al. Mol Ther Methods Clin Dev. 2014 Oct 22;1:14048. doi: 10.1038/mtm.2014.48. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015986 Free PMC article.

2

Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes.

Cavelti-Weder C, Timper K, Seelig E, Keller C, Osranek M, Lässing U, Spohn G, Maurer P, Müller P, Jennings GT, Willers J, Saudan P, Donath MY, Bachmann MF. Cavelti-Weder C, et al. Among authors: spohn g. Mol Ther. 2016 May;24(5):1003-12. doi: 10.1038/mt.2015.227. Epub 2015 Dec 21. Mol Ther. 2016. PMID: 26686385 Free PMC article. Clinical Trial.

3

Therapeutic vaccination to block receptor-ligand interactions.

Spohn G, Bachmann MF. Spohn G, et al. Expert Opin Biol Ther. 2003 Jun;3(3):469-76. doi: 10.1517/14712598.3.3.469. Expert Opin Biol Ther. 2003. PMID: 12783615 Review.

4

Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles.

Spohn G, Schwarz K, Maurer P, Illges H, Rajasekaran N, Choi Y, Jennings GT, Bachmann MF. Spohn G, et al. J Immunol. 2005 Nov 1;175(9):6211-8. doi: 10.4049/jimmunol.175.9.6211. J Immunol. 2005. PMID: 16237119

5

A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis.

Spohn G, Guler R, Johansen P, Keller I, Jacobs M, Beck M, Rohner F, Bauer M, Dietmeier K, Kündig TM, Jennings GT, Brombacher F, Bachmann MF. Spohn G, et al. J Immunol. 2007 Jun 1;178(11):7450-7. doi: 10.4049/jimmunol.178.11.7450. J Immunol. 2007. PMID: 17513796

6

Exploiting viral properties for the rational design of modern vaccines.

Spohn G, Bachmann MF. Spohn G, et al. Expert Rev Vaccines. 2008 Feb;7(1):43-54. doi: 10.1586/14760584.7.1.43. Expert Rev Vaccines. 2008. PMID: 18251693 Review.

7

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis.

Spohn G, Keller I, Beck M, Grest P, Jennings GT, Bachmann MF. Spohn G, et al. Eur J Immunol. 2008 Mar;38(3):877-87. doi: 10.1002/eji.200737989. Eur J Immunol. 2008. PMID: 18253928 Free article.

8

A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.

Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF. Spohn G, et al. Virol J. 2010 Jul 6;7:146. doi: 10.1186/1743-422X-7-146. Virol J. 2010. PMID: 20604940 Free PMC article.

9

Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice.

Guler R, Parihar SP, Spohn G, Johansen P, Brombacher F, Bachmann MF. Guler R, et al. Among authors: spohn g. Vaccine. 2011 Feb 1;29(6):1339-46. doi: 10.1016/j.vaccine.2010.10.045. Epub 2010 Nov 18. Vaccine. 2011. PMID: 21093494

10

A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis.

Tissot AC, Spohn G, Jennings GT, Shamshiev A, Kurrer MO, Windak R, Meier M, Viesti M, Hersberger M, Kündig TM, Ricci R, Bachmann MF. Tissot AC, et al. Among authors: spohn g. Eur J Immunol. 2013 Mar;43(3):716-22. doi: 10.1002/eji.201242687. Epub 2013 Jan 28. Eur J Immunol. 2013. PMID: 23254454 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

63 results

Search Page